Article CommentaryWhite Paper
Open Access
Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice
P.M. Cogswell, J.A. Barakos, F. Barkhof, T.S. Benzinger, C.R. Jack, T.Y. Poussaint, C.A. Raji, V.K. Ramanan and C.T. Whitlow
American Journal of Neuroradiology September 2022, 43 (9) E19-E35; DOI: https://doi.org/10.3174/ajnr.A7586
P.M. Cogswell
aFrom the Departments of Radiology (P.M.C., C.R.J.)
J.A. Barakos
cDepartment of Radiology (J.A.B.), California Pacific Medical Center, San Francisco, California
F. Barkhof
dDepartments of Radiology (F.B.)
eNuclear Medicine (F.B.), VU University Medical Center, Amsterdam, the Netherlands
fQueen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London, UK
T.S. Benzinger
gDepartments of Radiology (T.S.B., C.A.R.)
hNeurosurgery (T.S.B.)
C.R. Jack Jr.
aFrom the Departments of Radiology (P.M.C., C.R.J.)
T.Y. Poussaint
jDepartment of Radiology (T.Y.P.), Boston Children’s Hospital, Boston, Massachusetts
C.A. Raji
gDepartments of Radiology (T.S.B., C.A.R.)
iNeurology (C.A.R.),Washington University School of Medicine, St. Louis, Missouri
V.K. Ramanan
bNeurology (V.K.R.), Mayo Clinic, Rochester, Minnesota
C.T. Whitlow
kDepartments of Radiology (C.T.W.)
lBiomedical Engineering (C.T.W.), Wake Forest School of Medicine, Winston-Salem, North Carolina

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
American Journal of Neuroradiology
Vol. 43, Issue 9
1 Sep 2022
Advertisement
P.M. Cogswell, J.A. Barakos, F. Barkhof, T.S. Benzinger, C.R. Jack, T.Y. Poussaint, C.A. Raji, V.K. Ramanan, C.T. Whitlow
Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice
American Journal of Neuroradiology Sep 2022, 43 (9) E19-E35; DOI: 10.3174/ajnr.A7586
Jump to section
Related Articles
- No related articles found.
Cited By...
- Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies
- Spontaneous haemorrhage in subdural hygroma in an Alzheimers patient on lecanemab
- Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities
- Brain magnetic resonance imaging software to support dementia diagnosis in routine clinical practice: a barrier to adoption study in the National Health Service (NHS) England
- Donanemab outperformed Aducanumab and Lecanemab on cognitive, but not on biomarker and safety outcomes: systematic review, frequentist and Bayesian network meta-analyses
- Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-{beta}-Amyloid Monoclonal Antibody Treatment
- Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know
- Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology
- Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?
- Brain Shrinkage in Anti-{beta}-Amyloid Alzheimer Trials: Neurodegeneration or Pseudoatrophy?
- CAA-ri and ARIA: Two Faces of the Same Coin?
- Reply:
- MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?
This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.
More in this TOC Section
Similar Articles
Advertisement